Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lumiracoxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 11/20 | 1.00 |
| ▸ | PTGS1 | P23219 | 4/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 2/20 | 1.00 |
| ▸ | NR1I3 | Q14994 | 2/20 | 1.00 |
| ▸ | PPARG | P37231 | 1/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 2/20 | 0.63 |
| ▸ | TTR | P02766 | 2/20 | 0.56 |
| ▸ | CXCL8 | P10145 | 2/20 | 0.56 |
| ▸ | AKR1B10 | O60218 | 1/20 | 0.56 |
| ▸ | UGT1A9 | O60656 | 1/20 | 0.56 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.56 |
| ▸ | MT-CO2 | P00403 | 1/20 | 0.56 |
| ▸ | ALB | P02768 | 1/20 | 0.56 |
| ▸ | UGT1A6 | P19224 | 1/20 | 0.56 |
| ▸ | UGT1A1 | P22309 | 1/20 | 0.56 |
| ▸ | CXCR1 | P25024 | 1/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.56 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.56 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.56 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lumiracoxib SCHEMBL29377334 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL4479 | 1.00 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL27680523 | 0.99 | PTGS2 (0.98) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| Lumiracoxib SCHEMBL6063194 | 0.93 | PTGS2 (0.87) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL1031733 | 0.91 | PTGS2 (1.00) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17917294 | 0.91 | PTGS2 (0.85) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5533958 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL3120262 | 0.90 | PTGS2 (0.82) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL17208147 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG | |
| SCHEMBL5534966 | 0.88 | PTGS2 (0.79) | PTGS2PTGS1ABCB11NR1I3PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112839649-B | CXCR4 inhibitor compositions and methods of making and using the same | X4 制药有限公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| EP-4615455-A2 | IRAK DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2025-09-17 | — | — | EP | disclosed |
| WO-2025137537-A1 | COMPOSITIONS AND METHODS FOR TREATING MYC-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| WO-2025137548-A1 | COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING MYC-MEDIATED DISEASES | ARRAKIS THERAPEUTICS, INC. (US) | 2025-06-26 | — | — | WO | disclosed |
| CN-113454124-B9 | Combination therapies for ARM and natural killer cells | 克莱奥药品有限公司 | 2025-05-30 | — | — | CN | disclosed |
| CN-120051456-A | Substituted pyridone GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2025-05-27 | — | — | CN | disclosed |
| CN-120019047-A | Heteroaryl carboxamides and related GPR84 antagonists and uses thereof | 里米诺生物科学有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-119954725-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-119874700-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2025-04-25 | — | — | CN | disclosed |
| CN-109952303-B | TYK2 inhibitor and application thereof | 林伯士拉克许米公司 | 2022-10-21 | — | — | CN | disclosed |
| CN-115209897-A | Rapamycin analogs and uses thereof | 安纳库利亚治疗公司 | 2022-10-18 | — | — | CN | disclosed |
| WO-2022213062-A1 | HPK1 ANTAGONISTS AND USES THEREOF | Nimbus Saturn, Inc. (US) | 2022-10-06 | — | — | WO | disclosed |
| CN-110582501-B | TYK2 inhibitor, use and production method thereof | 林伯士拉克许米公司 | 2022-09-23 | — | — | CN | disclosed |
| CN-115052627-A | IRAK degrading agents and uses thereof | 凯麦拉医疗公司 | 2022-09-13 | — | — | CN | disclosed |
| CN-115038688-A | USP30 inhibitors and uses thereof | 文森雷生物科学股份有限公司 | 2022-09-09 | — | — | CN | disclosed |
| CN-114945366-A | HPK1 antagonists and uses thereof | 林伯士萨顿公司 | 2022-08-26 | — | — | CN | disclosed |
| CN-114466839-A | TEAD inhibitors and uses thereof | 医肯纳肿瘤学公司 | 2022-05-10 | — | — | CN | disclosed |
| CN-114401732-A | CD38 binding agents and uses thereof | 克莱奥药品有限公司 | 2022-04-26 | — | — | CN | disclosed |
| CN-114206869-A | CXCR4 inhibitors and uses thereof | X4 制药有限公司 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124309-A1 | STAT6 DEGRADERS AND USES THEREOF | STAT6, NCOR2, NCOR1 | PTGS2 541/4885PTGS1 841/4885ABCB11 1715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.